Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06504368 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
A Phase 1 study of Solid Tumors, Adult, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT06504368 is a Phase 1 study of Solid Tumors, Adult that is actively recruiting participants, run by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The registered enrollment target is 32 participants, below the 254-participant average among 5 other Solid Tumors, Adult trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06504368, a Phase 1 study of Solid Tumors, Adult, is actively recruiting participants, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period.
Conditions Studied
Interventions
- DRUG DCR-PDL1
Study Locations (2)
Texas
- NEXT Oncology - Irving
- Next Oncology - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-05-29 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06504368
The ClinicalTrials.gov registry entry for NCT06504368 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 254-participant average among 5 other Solid Tumors, Adult trials with a reported enrollment target (87% lower). The listed sponsor is Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors, Adult appearing as the primary indexed condition, and to 1 intervention - of which DCR-PDL1 is the first listed.
NCT06504368 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06504368 about?
NCT06504368 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors". The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based ...
What is the current status of trial NCT06504368?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-05-29. Estimated completion is 2027-12-31.
What conditions does trial NCT06504368 study?
This clinical trial studies the following conditions: Solid Tumors, Adult.
What interventions are being tested in trial NCT06504368?
The interventions under investigation include: DCR-PDL1 (DRUG).
Who is sponsoring clinical trial NCT06504368?
This trial is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06504368 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
RECRUITING · Phase 1
-
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
RECRUITING · Phase 1
-
Imaging of Solid Tumors Using FAP-2286
RECRUITING · Phase 1
-
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.